RT Journal Article
SR Electronic
T1 Aortic stenosis post-COVID-19: A mathematical model on waiting lists and mortality
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.11.21266212
DO 10.1101/2021.11.11.21266212
A1 Stickels, Christian P
A1 Nadarajah, Ramesh
A1 Gale, Chris P
A1 Jiang, Houyuan
A1 Sharkey, Kieran J
A1 Gibbison, Ben
A1 Holliman, Nick
A1 Lombardo, Sara
A1 Schewe, Lars
A1 Sommacal, Matteo
A1 Sun, Louise
A1 Weir-McCall, Jonathan
A1 Cheema, Katherine
A1 Rudd, James H F
A1 Mamas, Mamas A.
A1 Erhun, Feryal
YR 2021
UL http://medrxiv.org/content/early/2021/11/14/2021.11.11.21266212.abstract
AB Objectives To provide estimates for how different treatment pathways for the management of severe aortic stenosis (AS) may affect NHS England waiting list duration and associated mortality.Design We constructed a mathematical model of the excess waiting list and found the closed-form analytic solution to that model. From published data, we calculated estimates for how the following strategies may affect the time to clear the backlog of patients waiting for treatment and the associated waiting list mortality.Interventions 1) increasing the capacity for the treatment of severe AS, 2) converting proportions of cases from surgery to transcatheter aortic valve implantation, and 3) a combination of these two.Results In a capacitated system, clearing the backlog by returning to pre-COVID-19 capacity is not possible. A conversion rate of 50% would clear the backlog within 666 (95% CI, 533–848) days with 1419 (95% CI, 597–2189) deaths whilst waiting during this time. A 20% capacity increase would require 535 (95% CI, 434–666) days, with an associated mortality of 1172 (95% CI, 466–1859). A combination of converting 40% cases and increasing capacity by 20% would clear the backlog within a year (343 (95% CI, 281–410) days) with 784 (95% CI, 292–1324) deaths whilst awaiting treatment.Conclusion A strategy change to the management of severe AS is required to reduce the NHS backlog and waiting list deaths during the post-COVID-19 ‘recovery’ period. However, plausible adaptations will still incur a substantial wait and many hundreds dying without treatment.Competing Interest StatementCG acknowledges grants not related to this project from Abbott, the British Heart Foundation, and Deputy Editorship at EuroHeart. BG acknowledges grants not related to this project from the David Telling Charitable Trust, and the Biotechnology and Biological Sciences Research Council, he additionally declared Associate Editorship of Anesthesia Journal, and being the chair DMSC for the COPIA Trial. All other authors confirm that they have no competing interests to declare.Funding StatementCS acknowledges support from the EPSRC (DTC studentship) and an in-principle, but not yet confirmed, funding from the Newton Institute for carrying out his work in this project. HJ and FE acknowledge partial support by the EPSRC Cambridge Centre for Mathematics of Information in Healthcare. BG is supported by the NIHR Bristol Biomedical Research Centre at the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust. JHFR is part-supported by the NIHR Cambridge Biomedical Research Centre, the British Heart Foundation, HEFCE, the EPSRC Cambridge Centre for Mathematics of Information in Healthcare and the Wellcome Trust. None of these funding sources had an impact on the design, data analysis, writing of, or decision to publish this paper.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis manuscript does not present new experimental data.